Literature DB >> 19798509

Monoclonal antibody specific for IDH1 R132H mutation.

David Capper1, Hanswalter Zentgraf, Jörg Balss, Christian Hartmann, Andreas von Deimling.   

Abstract

IDH1 R132H mutations occur in approximately 70% of astrocytomas and oligodendroglial tumors. We developed a mouse monoclonal antibody targeting the IDH1 R132H mutation. Here, we show the high specificity and sensitivity of this antibody on Western blots and tissue sections from formalin fixed paraffin embedded tumor specimens. This antibody is highly useful for tumor classification, in detecting single infiltrating tumor cells and for the characterization of the cellular role of mutant IDH1 protein.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19798509     DOI: 10.1007/s00401-009-0595-z

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  148 in total

1.  Prognostic stratification of gliomatosis cerebri by IDH1 R132H and INA expression.

Authors:  Virginie Desestret; Pietro Ciccarino; François Ducray; Emmanuelle Crinière; Blandine Boisselier; Marianne Labussière; Marc Polivka; Ahmed Idbaih; Gentian Kaloshi; Andreas von Deimling; Khe Hoang-Xuan; Jean-Yves Delattre; Karima Mokhtari; Marc Sanson
Journal:  J Neurooncol       Date:  2011-04-24       Impact factor: 4.130

2.  Low rate of R132H IDH1 mutation in infratentorial and spinal cord grade II and III diffuse gliomas.

Authors:  Benjamin Ellezam; Brett J Theeler; Tobias Walbert; Aaron G Mammoser; Craig Horbinski; Bette K Kleinschmidt-DeMasters; Arie Perry; Vinay Puduvalli; Gregory N Fuller; Janet M Bruner; Kenneth D Aldape
Journal:  Acta Neuropathol       Date:  2012-07-08       Impact factor: 17.088

3.  The relationship between Cho/NAA and glioma metabolism: implementation for margin delineation of cerebral gliomas.

Authors:  Jun Guo; Chengjun Yao; Hong Chen; Dongxiao Zhuang; Weijun Tang; Guang Ren; Yin Wang; Jinsong Wu; Fengping Huang; Liangfu Zhou
Journal:  Acta Neurochir (Wien)       Date:  2012-06-23       Impact factor: 2.216

Review 4.  Detection of oncogenic IDH1 mutations using magnetic resonance spectroscopy of 2-hydroxyglutarate.

Authors:  Ovidiu C Andronesi; Otto Rapalino; Elizabeth Gerstner; Andrew Chi; Tracy T Batchelor; Dan P Cahill; A Gregory Sorensen; Bruce R Rosen
Journal:  J Clin Invest       Date:  2013-09-03       Impact factor: 14.808

5.  Prognostic Value of Preoperative MRI Metrics for Diffuse Lower-Grade Glioma Molecular Subtypes.

Authors:  P Darvishi; P P Batchala; J T Patrie; L M Poisson; M-B Lopes; R Jain; C E Fadul; D Schiff; S H Patel
Journal:  AJNR Am J Neuroradiol       Date:  2020-04-23       Impact factor: 3.825

6.  The 2016 revision of the WHO Classification of Central Nervous System Tumours: retrospective application to a cohort of diffuse gliomas.

Authors:  Te Whiti Rogers; Gurvinder Toor; Katharine Drummond; Craig Love; Kathryn Field; Rebecca Asher; Alpha Tsui; Michael Buckland; Michael Gonzales
Journal:  J Neurooncol       Date:  2017-12-07       Impact factor: 4.130

Review 7.  Glioblastoma targeted therapy: updated approaches from recent biological insights.

Authors:  M Touat; A Idbaih; M Sanson; K L Ligon
Journal:  Ann Oncol       Date:  2017-07-01       Impact factor: 32.976

8.  Detection of 2-hydroxyglutaric acid in vivo by proton magnetic resonance spectroscopy in U87 glioma cells overexpressing isocitrate dehydrogenase-1 mutation.

Authors:  Jelena Lazovic; Horacio Soto; David Piccioni; Jerry R Lou; Sichen Li; Leili Mirsadraei; William Yong; Robert Prins; Linda M Liau; Benjamin M Ellingson; Timothy F Cloughesy; Albert Lai; Whitney B Pope
Journal:  Neuro Oncol       Date:  2012-10-22       Impact factor: 12.300

9.  Something old and something new about molecular diagnostics in gliomas.

Authors:  Craig Horbinski
Journal:  Surg Pathol Clin       Date:  2012-12-01

10.  Neuroimaging-Based Classification Algorithm for Predicting 1p/19q-Codeletion Status in IDH-Mutant Lower Grade Gliomas.

Authors:  P P Batchala; T J E Muttikkal; J H Donahue; J T Patrie; D Schiff; C E Fadul; E K Mrachek; M-B Lopes; R Jain; S H Patel
Journal:  AJNR Am J Neuroradiol       Date:  2019-01-31       Impact factor: 3.825

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.